Clinical and regulatory milestone payments.

No definition available.

Name:	mtem_ClinicalAndRegulatoryMilestonePayments
Namespace Prefix:	mtem_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments receivable post option exercise.

+ References

No definition available.

+ Details

Name:	mtem_MilestonePaymentsReceivablePostOptionExercise
Namespace Prefix:	mtem_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of product and development grant awarded.

+ References

No definition available.

+ Details

Name:	mtem_ProductDevelopmentGrantAward
Namespace Prefix:	mtem_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Reimbursement amounts submitted in excess of amounts received are recorded as receivables.

+ References

No definition available.

+ Details

Name:	mtem_ReimbursementAmountsReceivedInExcessOfGrantRecordedAsReceivables
Namespace Prefix:	mtem_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research and development collaboration agreements.

+ References

No definition available.

+ Details

Name:	mtem_ResearchAndDevelopmentCollaborationAgreementsLineItems
Namespace Prefix:	mtem_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and development revenues from collaboration agreements.

+ References

No definition available.

+ Details

Name:	mtem_ResearchAndDevelopmentRevenuesFromCollaborationAgreements
Namespace Prefix:	mtem_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Transaction price allocated to performance obligations.

+ References

No definition available.

+ Details

Name:	mtem_TransactionPriceAllocatedToPerformanceObligations
Namespace Prefix:	mtem_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	mtem_UpfrontPayment
Namespace Prefix:	mtem_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126928961&loc=SL5834089-161433

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mtem_GrantAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=mtem_GrantsRevenueReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mtem_CancerPreventionAndResearchInstituteOfTexasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mtem_CancerResearchGrantContractMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mtem_TakedaMultiTargetAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=mtem_TakedaPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mtem_VertexCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mtem_BristolMyersSquibbCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mtem_SalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mtem_TakedaDevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research and Development Agreements - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended				6 Months Ended
	Aug. 31, 2021	Feb. 28, 2021	Sep. 30, 2018	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Research And Development Collaboration Agreements [Line Items]
Research and development revenue recognized				$ 4,417,000			$ 15,134,000	$ 12,903,000	$ 18,354,000
Revenue from grant				4,417,000			$ 15,134,000	12,903,000	18,354,000
Grant
Research And Development Collaboration Agreements [Line Items]
Revenue from grant								0	$ 0
Grant Agreements \| Grants Revenue Receivable
Research And Development Collaboration Agreements [Line Items]
Reimbursement amounts submitted in excess of amounts received are recorded as receivables				0		$ 0		0
Cancer Prevention and Research Institute of Texas \| CPRIT Agreement
Research And Development Collaboration Agreements [Line Items]
Product development grant awarded			$ 15,200,000
Takeda Multi-Target Agreement \| Takeda Pharmaceuticals Inc
Research And Development Collaboration Agreements [Line Items]
Deferred revenue				0		2,600,000		0
Research and development revenue recognized					$ 2,600,000
Vertex Collaboration Agreement
Research And Development Collaboration Agreements [Line Items]
Research and development revenue recognized						14,600,000
Bristol Myers Squibb Collaboration Agreement
Research And Development Collaboration Agreements [Line Items]
Upfront payment		$ 70,000,000.0
Milestone payments receivable if option is exercised		874,500,000
Transaction price allocated to performance obligations		70,000,000.0
Deferred revenue, current				32,700,000		32,800,000		32,700,000
Deferred revenue, non-current				$ 22,700,000		$ 30,700,000		$ 22,700,000
Bristol Myers Squibb Collaboration Agreement \| Sales Milestone
Research And Development Collaboration Agreements [Line Items]
Milestone payments receivable if option is exercised		$ 450,000,000.0
Maximum \| Takeda Development and License Agreement
Research And Development Collaboration Agreements [Line Items]
Clinical and regulatory milestone payments	$ 22,250,000